复合化疗药物的量评估:九个复合药房之间的比较
Samantha R Bajorek1, Trina N Hazzah1,2, John D Chretin1,3
1VCA West Los Angeles, Los Angeles, California, USA.
Veterinary and comparative oncology
|August 20, 2024
概括
兽医中复合化疗药物显示出显著的变化. 超过29%的样本超出了FDA的限制,503B药房的药品数量比503A药房更一致.
科学领域:
- 兽医药理学 兽医药理学
- 制药复合物 制药复合物
- 药品质量控制 药品质量控制
背景情况:
- 复合化疗配方在兽医中广泛使用.
- 确保这些配方中药物的精确含量对于患者的安全和治疗疗效至关重要.
- 复合药物剂量的变化可能导致剂量不足或过量,影响治疗结果.
研究的目的:
- 评估从兽医复合剂药房中获得的化合物ambucil和cyclophosphamide的实际药物量.
- 为了比较503A和503B监管药房之间的药物量准确性.
- 评估药品量在单个药房和批量中的异质性.
主要方法:
- 这项研究包括9家兽医复合药店 (八家503A,一家503B).
- 从每家药房抽取两批样品,并分析多个囊.
- 实际药物度被量化并与预期 (处方) 度进行比较.
主要成果:
- 68个复合样本中有20个 (29%) 超过了FDA可接受的±10%差异限制.
- ambucil的样本显示出较高的差异率 (60%) 与环胺 (40%) 相比.
- 被指定为503B的药房表现出更一致的药物量 (平均差异和异质性较低) 比503A药房对这两种药物.
结论:
- 在兽医中使用的化合物ambucil 和 cyclophosphamide 可以显示药物剂量的显著变化.
- 虽然503B药房显示出更高的可靠性,但仍观察到可变性,表明潜在的风险.
- 需要采取进一步的质量控制措施,以确保兽医实践中复合化疗药物的准确性和一致性.
更多相关视频
相关概念视频
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Three-Compartment Open Model
172
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
172
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
68
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
68
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
52
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
52


